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A B S T R A C T
Background
Chronic abdominal pain is one of the major symptoms in people with chronic pancreatitis. The role of pregabalin in people with
chronic pancreatic pain due to chronic pancreatitis is uncertain.
Objectives
To assess the benefits and harms of pregabalin in people with chronic abdominal pain due to chronic pancreatitis.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library 2015, issue 6, and MEDLINE,
EMBASE, Science Citation Index Expanded, trials registers until June 2015. We also searched the references of included trials to
identify further trials.
Selection criteria
We considered only randomised controlled trials (RCT) performed in people with chronic pancreatic pain due to chronic pancreatitis,
irrespective of language, blinding, or publication status for inclusion in the review.
Data collection and analysis
Two review authors independently identified trials and independently extracted data. We calculated the risk ratio (RR) or mean
difference (MD) with 95% confidence intervals (CI) with RevMan 5, based on intention-to-treat analysis.
Main results
Only one study, funded by Pfizer, met the inclusion criteria for the review. A total of 64 participants (with chronic pain due to chronic
pancreatitis) were randomly assigned to receive escalating doses of pregabalin (150 mg per day to 600 mg per day; 34 participants) or
matching placebo (30 participants). Participants received pregabalin or placebo for three weeks on an outpatient basis; the outcomeswere
measured at the end of the treatment (i.e. three weeks from commencement of treatment). Potential participants taking concomitant
analgesic medication and expected to stay on a stable regime during the trial were allowed to enter the study. This trial was at low risk
of bias. The overall quality of evidence was low or moderate.
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Only the short-term outcomes were available in this trial. The medium and long-term outcomes, number of work days lost, and length
of hospital stay due to admissions for pain control were not available. This trial found that the changes in opiate use (MD -26.00 mg;
95% CI -47.36 to -4.64; participants = 64; moderate-quality evidence), and pain score percentage changes from baseline (MD -12.00;
95% CI -21.82 to -2.18; participants = 64; moderate-quality evidence) were better in participants taking pregabalin compared to those
taking placebo. This trial also found that there were more adverse events in participants taking pregabalin compared to those taking
placebo (RR 1.71; 95% CI 1.20 to 2.43; participants = 64). The differences between pregabalin and placebo were imprecise for short-
term health-related quality of life measured with the EORTC CLQ-30 questionnaire (MD 11.40; 95% CI -3.28 to 26.08; participants
= 64; moderate-quality evidence), proportion of people with serious adverse events (RR 1.76; 95% CI 0.35 to 8.96; participants = 64;
low-quality evidence), and proportion of people requiring hospital admissions (RR 0.44; 95% CI 0.04 to 4.62; participants = 64; low
quality evidence).
Authors’ conclusions
Based on low- to moderate-quality evidence, short-term use of pregabalin decreases short-term opiate use, and short-term pain scores,
but increases the adverse events compared to placebo, in people with chronic pain due to chronic pancreatitis. The clinical implication
of the decreases in short-term opiate use and short-term pain scores is not known.
Future trials assessing the role of pregabalin in decreasing chronic pain in chronic pancreatitis should assess the medium- or long-term
effects of pregabalin and should include outcomes such as, quality of life, treatment-related adverse events, number of work days lost,
number of hospital admissions, and the length of hospital stay, in addition to pain scores, to assess the clinical and socioeconomic
impact.
P L A I N L A N G U A G E S U M M A R Y
Pregabalin for decreasing abdominal pain in people with chronic pancreatitis
Review question
Is pregabalin useful in decreasing abdominal pain in people with chronic pancreatitis?
Background
The pancreas is an abdominal organ that secretes several digestive enzymes into the pancreatic ductal system, which empties into the
small bowel. It also comprises the Islets of Langerhans, which secrete several hormones, including insulin. Chronic pancreatitis is long-
standing and progressive inflammation of the pancreas resulting in destruction and replacement of pancreatic tissue with fibrous tissue.
This may lead to a shortage of digestive enzymes and insulin (helps regulate blood sugar), leading to diabetes (a lifelong condition in
which a person’s blood sugar level becomes too high). Alcohol is considered the main cause but others include: smoking, some drugs,
and a variety of other disorders. Chronic abdominal pain is the major symptom of chronic pancreatitis. The pain is usually in the
upper abdomen and is usually described as deep, penetrating, and radiating to the back. Various theories exist about the reason for
pain in chronic pancreatitis. One theory is that the disease process affects the nerves supplying the pancreas. Pregabalin inhibits the
transmission of pain through the nerves. Pregabalin may decrease pain in people with chronic pancreatitis, but may also produce a
number of side-effects. Some common side-effects include: excessive sleepiness, blurred vision, double vision, dry mouth, constipation,
vomiting, excessive wind, feeling excited, confusion, reduced sexual desire, irritability, feeling dizzy, feeling unsteady, tremors, speech
difficulty, tingling or pricking (’pins and needles’) sensation, and disturbances of attention and memory. Less frequent, but serious
adverse events include: fainting episodes, heart failure, and reversible kidney failure. This review included all studies 22 June 2015, on
the benefits and harms of using pregabalin to treat chronic pain in people with chronic pancreatitis.
Study characteristics
We only found one study funded by Pfizer that met our inclusion criteria. A total of 64 participants with chronic pain due to chronic
pancreatitis received either increasing doses of pregabalin (150 mg per day to 600 mg per day; 34 participants) or matching placebo
(sham treatment; 30 participants) on an outpatient basis. The decision about whether a participant received pregabalin or placebo
was made using methods similar to toss of a coin, to ensure that the participants in the two groups were similar. Participants received
pregabalin or placebo for three weeks, then the outcomes were measured. Potential participants taking other pain-killers were allowed
to take part in the study. Thus, this trial evaluates the role of pregabalin in addition to other analgesics for decreasing chronic abdominal
pain due to chronic pancreatitis.
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Key results
Only the short-term outcomes were available in this trial. This trial found that the changes in opiate use (drugs similar to morphine),
and pain scores from baseline were better in participants taking pregabalin compared to those taking placebo. It was not clear whether
these changes had a significant impact on the life of the participants.This trial also found that there weremore side-effects in participants
taking pregabalin compared to those taking placebo. The differences between pregabalin and placebo were imprecise for short-term
health-related quality of life, percentage of people with serious side-effects, and percentage of people requiring hospital admissions.
Medium- and long-term outcomes, number of work days lost, and length of hospital stay were not available in this trial.
Quality of the evidence
The quality of evidence was low or moderate. As a result, further studies are required on this topic.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Pregabalin versus placebo for decreasing pancreatic pain in chronic pancreatitis
Patient or population: patients with chronic pancreatitis and pancreatic pain
Settings: outpatient
Intervention: pregabalin
Control: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Placebo Pregabalin
Health-related quality of life
(short-term)
EORTC QLQ-C30
Follow-up: 3 weeks
The mean health-related qual-
ity of life (short-term) in the
control groups was
-1.7 points
The mean health-related qual-
ity of life (short-term) in the
intervention groups was
11.4 higher (3.28 lower to 26.
08 higher)
64
(1 study)
⊕⊕⊕©
moderate1
Serious adverse events
Follow-up: 3 weeks
67 per 1000 117 per 1000
(23 to 597)
RR 1.76
(0.35 to 8.96)
64
(1 study)
⊕⊕©©
low2,3
Opiate analgesic require-
ment (short-term)
Follow-up: median 3 weeks
The mean opiate analgesic re-
quirement (short-term) in the
control groups was -4 mg
The mean opiate analgesic re-
quirement (short-term) in the
intervention groups was
26 lower (47.36 to 4.64
lower)
64
(1 study)
⊕⊕⊕©
moderate1
Adverse events
Follow-up: 3 weeks
533 per 1000 912 per 1000
(640 to 1000)
RR 1.71
(1.2 to 2.43)
64
(1 study)
⊕⊕⊕©
moderate2
4
P
re
g
a
b
a
lin
fo
r
d
e
c
re
a
sin
g
p
a
n
c
re
a
tic
p
a
in
in
c
h
ro
n
ic
p
a
n
c
re
a
titis
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
6
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Pain scores (short-term)
Follow-up: 3 weeks
The mean pain scores (short-
term) in the control groups
was -24 percentage change
from baseline
The mean pain scores (short-
term) in the intervention
groups was
12 lower (22 to 2 lower)
64
(1 study)
⊕⊕⊕©
moderate1
Hospital admissions
Follow-up: 3 weeks
67 per 1000 29 per 1000
(3 to 308)
RR 0.44
(0.04 to 4.62)
64
(1 study)
⊕⊕©©
low2,3
The only trial included in this review did not report medium or long-term outcomes and did not report the number of work days lost and length of hospital stay (Olesen 2011).
Although the risk of bias in the trial was low and the quality of evidence is low to moderate for short-term outcomes, the short duration of the trial and follow-up (i.e. medium to long-term
outcomes were not available) and the lack of important clinical outcomes such as work days lost and length of hospital stay cause a major threat to external validity of the results as chronic
pancreatitis is a long-standing disorder and the treatment is aimed only at symptomatic control of chronic pancreatitis. As a result, the effectiveness and treatment-related complications may
be different between the short-term and the medium-term or long-term
*The basis for the assumed risk is the control group risk in the only study. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group
and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 There were fewer than 400 participants included in both groups (imprecision).
2 There were fewer than 300 events in both groups (imprecision).
3 The confidence intervals 1 and 0.75 or 1.25 or both (imprecision).
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B A C K G R O U N D
Description of the condition
Please see the glossary of terms in Appendix 1.
The pancreas is an abdominal organ that secretes several digestive
enzymes into the pancreatic ductal system, which empties into
the small bowel. It also comprises the Islets of Langerhans, which
secrete several hormones, including insulin (NCBI 2014).Chronic
pancreatitis is long-standing and progressive inflammation of the
pancreas resulting in destruction and replacement of pancreatic
tissue with fibrous tissue (structural deformity) (Braganza 2011).
This may lead to the functional deformity of exocrine pancreatic
insufficiency and endocrine pancreatic insufficiency (diabetes) (
Braganza 2011). Although previously considered as distinct from
acute pancreatitis (since the pancreas returns to normal after an
attack of acute pancreatitis), chronic pancreatitis is now considered
to belong to the spectrum of pancreatitis disorders that include
acute pancreatitis and acute recurrent pancreatitis, because of the
overlapping aetiology and symptoms (Braganza 2011).
The annual incidence of chronic pancreatitis ranges from1.5 to 7.9
per 100,000 population (Dite 2001; Dominguez-Munoz 2014;
Joergensen 2010; Spanier 2013; Yadav 2011). The prevalence of
chronic pancreatitis ranges from 17 to 49 per 100,000 population
(Dominguez-Munoz 2014; Joergensen 2010; Yadav 2011). The
annual mortality rate attributable to chronic pancreatitis is around
one to four per million people (Dominguez-Munoz 2014; Spanier
2013). Alcohol is the main cause of chronic pancreatitis (Dite
2001; Joergensen 2010; Yadav 2011).Other causes include: smok-
ing; drugs such as valproate, thiazide, and oestrogens; other predis-
posing metabolic disorders and diseases such as hypercalcaemia,
hyperparathyroidism, and chronic renal failure; infections such as
human immunodeficiency virus (HIV) and mumps; genetic mu-
tations such as SPINK1 or CFTR mutations; obstruction of the
main pancreatic duct due to cancer, scarring post ERCP (endo-
scopic retrograde cholangiopancreatography) or after an attack of
severe pancreatitis; recurrent pancreatitis; autoimmune pancreati-
tis; gallstones; and idiopathic pancreatitis (including tropical pan-
creatitis; Braganza 2011; Dominguez-Munoz 2014; Joergensen
2010). The reasons for these causes to result in chronic pancre-
atitis are poorly understood and various theories have been pro-
posed (Braganza 2011). Increasing age and male gender are associ-
ated with a higher incidence and prevalence of chronic pancreatitis
(Joergensen 2010; Spanier 2013; Yadav 2011).
While histopathological examination of a specimen of pancreas
obtained by wedge biopsy or excision provides the definitive diag-
nosis of chronic pancreatitis, this is not practical (Braganza 2011).
Invasive methods, such as reduction of bicarbonate in duode-
nal aspirate after stimulation with cholecystokinin or its analogue
caerulein and ductal abnormalities on ERCP, are neither available
routinely, nor can they be recommended routinely in patients with
chronic abdominal pain (Braganza 2011). Secretin enhancedmag-
netic resonance cholangiopancreatography (MRCP), endoscopic
ultrasound (EUS), and computed tomography (CT) scans are the
other tests that may be used for the diagnosis of chronic pancre-
atitis.
Various criteria have been used for the staging of chronic pancre-
atitis. Some of these are Ammann’s criteria (Ammann 1997), the
M-ANNHEIM criteria (named after the first letters of the causes
of pancreatitis; Schneider 2007), the revised Japanese clinical diag-
nostic criteria (Shimosegawa 2010), the Manchester classification
(Bagul 2006), and the Heidelberg criteria (Buchler 2009). The
presence of so many classifications is clear evidence of the lack of
consensus among experts about the staging of chronic pancreatitis.
The validity of these different criteria, in terms of reproducibility
and implications, has not been compared in order to allow the rec-
ommendation of one staging system over another. In general, the
criteria for staging chronic pancreatitis include one or more of the
following features: chronic abdominal pain, exocrine pancreatic
insufficiency (pancreatic enzyme deficiency that leads to indiges-
tion of food and is manifested clinically by steatorrhoea, bloating,
excessive flatulence, or established by decreased stool elastase), cal-
cifications in the pancreas, pancreatic ductal abnormalities, and
histopathological diagnosis. In addition to the symptoms men-
tioned above, patients may also develop symptoms related to com-
plications associated with chronic pancreatitis, such as diabetes,
pancreatic pseudocysts, and biliary obstruction (Braganza 2011).
Chronic abdominal pain is the major manifestation of chronic
pancreatitis. The pain is usually in the upper abdomen and is
usually described as deep, penetrating, and radiating to the back
(Fasanella 2007). Various theories exist as to the pathogenesis of
pain in patients with chronic pancreatitis. The major theories are
pancreatic duct hypertension caused by calcification and fibrosis
resulting from inflammation; increased pancreatic tissue pressure
due to fibrosis of the peripancreatic capsule and parenchyma; and
neural pain (Fasanella 2007). Due to the neural origin of pain,
treatments such as pregabalin (Olesen 2011), coeliac plexus blocks
and neurolysis (Puli 2009), and thoracic splanchnicectomy (divi-
sion of the thoracic splanchnic nerves, which carry the sympathetic
and sensory fibres from the abdominal organs including the pan-
creas; Bradley 2003) have been used to treat patients with chronic
pancreatitis.
Description of the intervention
Pregabalin is a derivative of γ -aminobutyric acid (GABA), an in-
hibitory neurotransmitter (Sills 2006). Pregabalin is given orally in
two or three divided doses daily (Martindale 2011). It is licensed
for use for a variety of indications including: epilepsy, generalised
anxiety disorder, neuropathic pain, and fibromyalgia (Martindale
2011). For neuropathic pain, the initial dose in the UK is 150 mg
daily, increased after three to seven days according to the patient’s
response to 300 mg daily, and then to 600 mg daily after another
seven days. Similar doses are licensed in the USA for the treatment
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of neuropathic pain, although a maximum daily dose of 300 mg
is recommended in diabetic neuropathy (Martindale 2011).
Common adverse events related to pregabalin include: dizziness,
somnolence, blurred vision, diplopia (double vision), dry mouth,
constipation, vomiting, flatulence, euphoria, confusion, reduced
libido, erectile dysfunction, irritability, vertigo, ataxia, tremor,
dysarthria, paraesthesia, fatigue, oedema, and disturbances of at-
tention, memory, co-ordination, and gait (Martindale 2011). Less
frequent and rare but serious adverse events include: fainting
episodes, heart failure, reversible renal failure, raised liver en-
zymes, rhabdomyolysis, breast enlargement, and gynaecomastia
(Martindale 2011). Hypersensitivity reactions manifesting as rash,
blisters, urticaria, dyspnoea, and wheezing have also been re-
ported (Martindale 2011). There is currently no evidence of any
metabolic interaction of pregabalin with other drugs.
How the intervention might work
Pregabalin inhibits the transmission of pain through the nerves.
However, the molecular mechanism of its action is not known.
Inhibition of calcium flow through high-voltage-gated calcium
channels containing theα2δ-1 subunit, resulting in decreased neu-
rotransmitter release and excitability of the pain nerve fibres, is
currently believed to be the mechanism of its action (Sills 2006).
Why it is important to do this review
There is currently no consensus on the management of pain in
patients with chronic pancreatitis. This review provides the best
level of evidence on the benefits and harms of pregabalin, and so
allow patients and the surgeons involved in their care to make
informed decisions.
O B J E C T I V E S
To assess the benefits and harms of pregabalin in people with
chronic pancreatitis with chronic abdominal pain.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs). We included
studies reported in full text, those published as an abstract only,
and unpublished data.
Types of participants
We included adults with chronic pancreatitis with chronic abdom-
inal pain. We excluded patients with pancreatic cancer.
Types of interventions
We included trials comparing pregabalin (irrespective of the dose)
with an inactive intervention (placebo or no intervention). We
accepted co-interventions, for example, the use of a pancreatic en-
zyme supplement or opiates, provided that they were used equally
in both groups.
Types of outcome measures
Primary outcomes
1. Health-related quality of life post-treatment (using any
validated scale, such as EQ-5D or SF-36; EuroQol 2014; Ware
2014). The EQ-5D assesses the quality of life under five
domains: mobility, self care, usual activities, pain or discomfort,
and anxiety or depression (EuroQol 2014). The SF-36 assesses
the quality of life under eight sections: vitality, physical
functioning, bodily pain, general health perceptions, physical
role functioning, emotional role functioning, social role
functioning, and mental health (Ware 2014).
i) Short-term (two weeks to three months).
ii) Medium-term (three months to five years).
iii) Long-term (more than five years).
2. Treatment-related serious adverse events such as heart or
renal failure (within three months). We accepted the following
definitions of serious adverse events.
i) ICH-GCP International Conference on
Harmonisation - Good Clinical Practice guideline (ICH-GCP
1996): serious adverse events defined as any untoward medical
occurrence that results in death, is life-threatening, requires
inpatient hospitalisation or prolongation of existing
hospitalisation, or results in persistent or significant disability or
incapacity.
ii) Other variations of ICH-GCP classifications such as
the US Food and Drug Administration (FDA) classification
(FDA 2006), or the Medicines and Healthcare products
Regulatory Agency (MHRA) classification (MHRA 2013).
3. Opiate requirement (in terms of the total amount required
during the follow-up period, and only from trials where opiates
were not used routinely).
i) Short-term (two weeks to three months).
ii) Medium-term (three months to five years).
iii) Long-term (more than five years).
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Secondary outcomes
1. Treatment-related adverse events (within three months;
dizziness, dry mouth). We accepted all adverse events reported by
the study author, irrespective of the severity of the adverse event.
2. Pain scores using a visual analogue scale.
i) Short-term (two weeks to three months).
ii) Medium-term (three months to five years).
iii) Long-term (more than five years).
3. Work days lost.
4. Number and duration of hospital admissions for control of
pain.
The choice of the above clinical outcomes was based on the ne-
cessity to assess whether pregabalin is safe and effective in terms
of decreasing pain and improving health-related quality of life in
patients with pancreatic pain. This information would provide the
data to assess the cost-effectiveness of pregabalin.
Reporting of the outcomes listed here was not an inclusion crite-
rion for the review.
Search methods for identification of studies
Electronic searches
We conducted a literature search to identify all published and
unpublished randomised controlled trials. The literature search
identified potential studies in all languages. We had planned to
translate the non-English language papers and fully assess them
for potential inclusion in the review as necessary.
We searched the following electronic databases for identifying po-
tential studies:
• Cochrane Central Register of Controlled Trials
(CENTRAL; The Cochrane Library 2015, Issue 6; Appendix 2);
• MEDLINE (1966 to June 2015; Appendix 3);
• EMBASE (1988 to June 2015; Appendix 4); and
• Science Citation Index (1982 to June 2015; Appendix 5).
We also conducted a search of ClinicalTrials.gov (Appendix 6),
and WHO ICTRP (World Health Organization - International
Clinical Trials Registry Platform; Appendix 7).
Searching other resources
We checked the reference lists of all primary studies and review
articles for additional references. We attempted to contact the
authors of identified trials and ask them to identify other published
and unpublished studies.
We searched for errata or retractions fromeligible trials on PubMed
on 23 June 2015.
Data collection and analysis
Selection of studies
Two review authors (KG and CL) independently screened the ti-
tles and abstracts of all the potential studies we identified as a re-
sult of the search and coded them as ’retrieve’ (eligible, potentially
eligible, or unclear) or ’do not retrieve’. We retrieved the full-text
study reports and two review authors (KG and CL) independently
screened the full text, identified studies for inclusion, and identi-
fied and recorded the reasons for exclusion of the ineligible studies.
We resolved any disagreement through discussion. We identified
and excluded duplicate references and collated multiple reports of
the same study so that each study rather than each report was the
unit of interest in the review. We recorded the selection process in
sufficient detail to complete a PRISMA flow diagram and ’Char-
acteristics of excluded studies’ table.
Data extraction and management
We used a standard data collection form for study characteristics
and outcome data. Two review authors (KG and CL) extracted the
following study characteristics from the included studies:
1. Methods: study design, total duration study and run-in,
number of study centres and location, study setting,
withdrawals, date of study.
2. Participants: number (N), mean age, age range, gender,
inclusion criteria, exclusion criteria.
3. Interventions: intervention, comparison, concomitant
interventions.
4. Outcomes: primary and secondary outcomes specified and
collected, time points reported.
5. Notes: funding for trial, notable conflicts of interest of trial
authors.
Two review authors (KG and CL) independently extracted out-
come data from the included studies. If outcomes were reported at
multiple time points, for example, short-term health-related qual-
ity of life was reported at two weeks and three weeks, we chose the
later time point (i.e. three weeks) for data extraction. If possible,
for time-to-event outcomes, we had planned to extract data to
calculate the natural logarithm of the hazard ratio and its standard
error, using themethods suggested by Parmar, et al (Parmar 1998).
We had planned to include all randomised participants for
medium-term and long-term outcomes (for example, quality of
life); this would not have been conditional upon the short-term
outcomes (for example, having a low- or high-quality of life index
at three weeks).
We had planned to note in the ’Characteristics of included stud-
ies’ table if outcome data were reported in an unusable way. We
resolved disagreements by consensus. One review author (KG)
copied the data from the data collection form into the Review
Manager file. We double checked that the data were entered cor-
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rectly by comparing the study reports with the data presentation
in the review.
Assessment of risk of bias in included studies
Two review authors (KG and CL) independently assessed the risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved any disagreement by discussion. We assessed the risk
of bias according to the following domains:
1. random sequence generation;
2. allocation concealment;
3. blinding of participants and personnel;
4. blinding of outcome assessment;
5. incomplete outcome data;
6. selective outcome reporting;
7. other bias.
We graded each potential source of bias as high, low, or unclear,
and provided a quote from the study report, together with a jus-
tification for our judgement in the ’Risk of bias’ table. We sum-
marised the ’Risk of bias’ judgements across different studies for
each of the domains listed. We considered blinding separately for
different key outcomes where necessary. Where information on
risk of bias related to unpublished data or correspondence with a
trialist, we had planned to note this in the ’Risk of bias’ table.
When considering treatment effects, we took into account the risk
of bias of the studies that contributed to that outcome.
Assessment of bias in conducting the systematic
review
We conducted the review according to the published protocol
and reported any deviations from it in the ’Differences between
protocol and review’ section of the systematic review.
Measures of treatment effect
We analysed dichotomous data (proportion of participants with
adverse events, serious adverse events, and number of hospital
admissions) as a risk ratio. We had planned to analyse continuous
data as a mean difference when the outcome was reported in the
same units (pain scores, number of work days lost, and duration of
hospital admissions for control of pain), or the same health-related
quality of life scale; or as a standardised mean difference when
different scales were used for measuring quality of life, or when
different opiates were used at different doses. We have ensured that
higher scores for continuous outcomes have the same meaning for
the particular outcome, explained the direction to the reader, and
reported where the directions were reversed, if this was necessary.
We had planned to calculate the rate ratio for outcomes such as
adverse events and serious adverse events, where it was possible
for the same person to develop more than one adverse event (or
serious adverse event). If the authors had calculated the rate ratio of
adverse events (or serious adverse events) in the intervention versus
the control group based on Poisson regression, we had planned to
obtain the rate ratio by the Poisson regressionmethod in preference
to the rate ratio calculated based on the number of adverse events
(or serious adverse events) during a certain period.We had planned
to calculate the hazard ratio for time-to-event outcomes such as
time-to-first adverse event (or serious adverse event).
We had planned to undertake meta-analyses only where this was
meaningful, i.e. if the treatments, participants, and the underlying
clinical question were similar enough for pooling to make sense.
A common way in which trialists indicate that they have skewed
data is by reportingmedians and interquartile ranges.Whenwe en-
countered this, we had planned to note that the data were skewed,
and consider the implications of this.
Where multiple trial arms were reported in a single trial, we had
planned to include only the relevant arms. If two comparisons had
to be entered into the samemeta-analysis (e.g. pregabalin low dose
versus placebo and pregabalin high dose versus placebo), we had
planned to halve the control group to avoid double counting. The
alternative way of including trials with multiple arms is to pool
the results of the pregabalin doses and compare this with placebo.
We had planned to perform a sensitivity analysis to determine if
the results of the two methods of dealing with multi-arm trials led
to different conclusions.
Unit of analysis issues
The unit of analysis was individual patients with chronic pan-
creatitis with abdominal pain. We did not anticipate any cluster-
randomised trials for this comparison, but if cluster-randomised
trials were identified, we had planned to obtain the effect esti-
mate, adjusted for the clustering effect. If this was not available,
we had planned to perform a sensitivity analysis by excluding the
trial from the meta-analysis, as the variance of the effect estimate
unadjusted for the cluster effect is less than the actual variance,
which is adjusted for the cluster effect giving inappropriately more
weight to the cluster-RCT in the meta-analysis.
Had we included cross-over randomised trials, we had planned to
include only the data prior to cross-over, and analyse the data in
the same way as parallel randomised trials.
Dealing with missing data
We would have attempted to contact investigators or sponsors in
order to verify key study characteristics and obtain missing nu-
merical outcome data when indicated (e.g. when a study was iden-
tified as an abstract only). If we were unable to obtain the infor-
mation from the investigators or study sponsors, we had planned
to impute the mean from the median (i.e. consider the median
as the mean) and the standard deviation from the standard error
or P values, according to the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011); we had planned to assess
the impact of including such studies in a sensitivity analysis, as
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indicated. If we were unable to calculate the standard deviation
from the standard error or P values, we had planned to impute the
standard deviation as the highest standard deviation in the remain-
ing trials included in the outcome, fully aware that this method of
imputation would decrease the weight of the studies in the meta-
analysis of mean difference, and shift the effect towards no effect
for the standardised mean difference.
Assessment of heterogeneity
We planned to use the I² statistic to measure heterogeneity among
the trials in each analysis. If we identified substantial heterogeneity,
as per the Cochrane Handbook for Systematic Reviews of Interven-
tions (greater than 50% to 60%; Higgins 2011), we had planned to
explore it by pre-specified subgroup analysis. We had also planned
to assess heterogeneity by evaluating whether there was good over-
lap of confidence intervals.
Assessment of reporting biases
We would have attempted to contact study authors to ask them
to provide missing outcome data. Where this was not possible,
and the missing data were thought to introduce serious bias, we
had planned to explore the impact of including such studies in the
overall assessment of results by a sensitivity analysis.
If we had been able to pool more than 10 trials, we had planned
to create and examine a funnel plot to explore possible publica-
tion biases. We had planned to use Egger’s test to determine the
statistical significance of the reporting bias (Egger 1997). We had
planned to consider a P value of less than 0.05 to be a statistically
significant reporting bias.
Data synthesis
We performed the analysis using RevMan 5.3 (Review Manager
2014). We had planned to use the Mantel-Haenszel method for
dichotomous data, the inverse variance method for continuous
data, and the generic inverse variance method for count and time-
to-event data. We had planned to use both the fixed-effect model
(Demets 1987), and the random-effects model (DerSimonian
1986), for the analysis. In case of discrepancy between the two
models, we had planned to report both results; otherwise we had
planned to report only the results from the fixed-effect model.
’Summary of findings’ table
We created a ’Summary of findings’ table using all of the out-
comes. We used the five GRADE considerations (study limita-
tions, consistency of effect, imprecision, indirectness, and publica-
tion bias) to assess the quality of the body of evidence as it related
to the studies that contributed data to the meta-analyses for the
pre-specified outcomes. We used the methods and recommenda-
tions described in Chapter 8.5 and Chapter 12 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011),
and used GRADEpro software. We justified all decisions to down-
grade or upgrade the quality of studies using footnotes, and made
comments to aid the reader’s understanding of the review where
necessary. We had planned to consider whether there was any ad-
ditional outcome information that could not be incorporated into
the meta-analyses, note this in the comments, and state if it sup-
ported or contradicted the information from the meta-analyses.
Subgroup analysis and investigation of heterogeneity
We had planned to carry out the following subgroup analyses:
1. Different doses of pregabalin (each different dose of
pregabalin).
2. Routine pancreatic enzyme supplementation versus no
pancreatic enzyme supplementation.
3. Participants in whom opiates were used routinely versus
participants in whom opiates were not used routinely.
We had planned to use all of the primary outcomes in subgroup
analyses (except for the outcome opiate requirement for the sub-
group analysis of routine opiate use versus no routine opiate use).
We had planned to use the formal Chi² test for subgroup differ-
ences to test for subgroup interactions.
Sensitivity analysis
We had planned to perform the following sensitivity analysis, de-
fined a priori, to assess the robustness of our conclusions:
1. exclude trials at unclear or high risk of bias (one of more of
the ’Risk of bias’ domains (other than blinding of surgeon)
classified as unclear or high);
2. exclude trials in which either the mean, standard deviation,
or both were imputed;
3. exclude cluster-RCTs in which the adjusted effect estimates
are not reported;
4. explore different methods of dealing with multi-arm trials
(please see Measures of treatment effect).
Reaching conclusions
We based our conclusions on the findings from the quantitative
and narrative synthesis of the included studies in this review. We
avoided making recommendations for practice; our implications
for research have given the reader a clear sense of where the focus
of future research in the area should be and what the remaining
uncertainties are.
R E S U L T S
Description of studies
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Results of the search
We identified 112 references through electronic searches of CEN-
TRAL (Wiley) (N = 6), MEDLINE (OvidSP) (N = 13), EM-
BASE (OvidSP) (N = 76), Science Citation Index expanded (N
= 11), ClinicalTrials.gov (N = 1), and WHO Trials register (N =
5). After removing duplicate references, there were 82 references.
We excluded 73 clearly irrelevant references through reading titles
and abstracts. A total of nine references were retrieved for further
assessment from the full publication. All the nine references were
eligible for inclusion in the review. All nine references were reports
of the same randomised controlled trial (Olesen 2011), which ful-
filled the inclusion criteria (Characteristics of included studies).
The reference flow is shown in Figure 1.
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Figure 1. Study flow diagram.
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Included studies
One randomised controlled trial (RCT) was included in this re-
view (Olesen 2011). This was a two-armed trial in which 64 par-
ticipants with chronic pancreatitis and pancreatic pain were ran-
domised to escalating doses of pregabalin (150 mg per day to 600
mg per day; 34 participants) or matching placebo (30 partici-
pants). Participants received pregabalin or placebo for three weeks
on an outpatient basis; the outcomes were measured at the end
of the treatment (i.e. three weeks from commencement of treat-
ment). Potential participants taking concomitant analgesic medi-
cation and expected to stay on a stable regime during the trial were
allowed to enter the study. There was no evidence of any baseline
differences in the pain scores or analgesic use between the groups.
The proportion of participants with obstructive jaundice was not
stated in the trial. The outcomes of interest for this review that
were reported in the trial included: health-related quality of life,
opiate analgesic requirement, adverse events and serious adverse
events, pain scores, and hospital readmissions. The trial also re-
ported several other surrogate outcomes that explored the mech-
anism of action of pregabalin (Olesen 2011).
Excluded studies
Wedid not exclude any reference after obtaining the full text, since
it was clear that none of the references met the inclusion criteria
on reading the titles and abstracts.
Risk of bias in included studies
The only trial included in this review was a trial at a low risk of
bias. The risk of bias in individual domains is shown in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each ’Risk of bias’ item for each included
study.
Allocation
The random sequence was generated by computer and was con-
cealed from researchers by the sponsor.
Blinding
Participants, healthcare providers, and outcome assessors were
blinded to the use of placebo.
Incomplete outcome data
All the participantswere included in the analyses, and an intention-
to-treat analysis was performed.
Selective reporting
The trial reported the important short-term outcomes that could
be expected to be reported.
Other potential sources of bias
We did not identify any other potential sources of bias in the trial.
However, it has to be noted that the trial was funded by a party
with a vested interest in the results.
Effects of interventions
See: Summary of findings for the main comparison Pregabalin
versus placebo for decreasing pancreatic pain in chronic
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pancreatitis
The only trial included in this review followed 64 participants
for three weeks after commencement of treatment (Olesen 2011).
So, only the short-term outcomes were available. The medium
and long-term outcomes were not available from this trial. The
trial did not report the number of work days lost and length of
hospital stay (Olesen 2011). Since there was only trial, we did not
assess heterogeneity, perform meta-analysis using fixed-effect or
random-effects model, assess reporting bias, or perform subgroup
or sensitivity analysis. A summary of the effect estimates is available
in the Summary of findings for the main comparison.
Primary outcomes
Health-related quality of life (short-term)
The trial reported change in health-related quality of life (HRQoL;
measured using EORTC CLQ-30 questionnaire) from the base-
line. This is a scale of 0 to 100 with higher values indicating a bet-
ter HRQoL.There was no statistically significant difference in the
change in HRQoL at three weeks favouring the pregabalin group
(MD 11.40; 95% CI -3.28 to 26.08; participants = 64; studies =
1; Analysis 1.1). It should be noted that standard deviation was
calculated from confidence intervals reported by the authors.
Serious adverse events
There was no statistically significant difference in the proportion
of people who developed serious adverse events between the two
groups (RR 1.76; 95% CI 0.35 to 8.96; participants = 64; studies
= 1; Analysis 1.2).
Opiate requirement (short-term)
The trial reported a change in opiate requirement (measured inmg
but the opiate used was not reported) from the baseline. There was
a statistically significant difference in the reduction in opiate use
at three weeks favouring the pregabalin group (MD -26.00 mg;
95% CI -47.36 to -4.64; participants = 64; studies = 1; Analysis
1.3). It should be noted that the standard deviation was calculated
from the P value reported by the authors.
Secondary outcomes
Adverse events
The proportion of people with adverse events was statistically sig-
nificantly more in the pregabalin group than placebo group (RR
1.71; 95% CI 1.20 to 2.43; participants = 64; studies = 1; Analysis
1.4.
Pain scores (short-term)
The trial reported percentage change in pain scores (measured us-
ing visual analogue scale) from the baseline. There was a statisti-
cally significant difference in the percentage change in pain scores
at three weeks favouring the pregabalin group (MD -12.00; 95%
CI -21.82 to -2.18; participants = 64; studies = 1; Analysis 1.5). It
should be noted that the standard deviation was calculated from
the confidence intervals reported by the authors.
Hospital admissions for control of pain
Therewas no statistically significant difference in the proportion of
people who required hospital admissions for pain control between
the two groups (RR 0.44; 95% CI 0.04 to 4.62; participants = 64;
studies = 1; Analysis 1.6.
D I S C U S S I O N
Summary of main results
We only identified one randomised controlled trial assessing the
effect of pregabalin in decreasing pancreatic pain in chronic pan-
creatitis (Olesen 2011). This trial found that opiate use and pain
scores were lower in participants taking pregabalin compared to
those taking placebo. This trial also found that there were more
adverse events in participants taking pregabalin compared to those
taking placebo. There was no statistically significant difference in
the short-term health-related quality of life, proportion of people
with serious adverse events, or in hospital admissions. The trial
did not assess medium and long-term outcomes, number of work
days lost, or length of hospital stay.
Overall completeness and applicability of
evidence
The trial only included patients with chronic pain due to chronic
pancreatitis, so the results are only applicable for people with these
diagnoses and symptoms. The benefits and harms of short-term
administration of pregabalin was reported, but these cannot be
extrapolated to benefits and harms in themedium- and long-term,
which may be entirely different from those in the short-term.
Quality of the evidence
The overall quality of the evidence was moderate or low. The risk
of bias was low in the trial. The major issue was the duration of
the trial and follow-up (i.e. medium to long-term outcomes were
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not available), and the lack of important clinical outcomes, such
as work days lost and length of hospital stay.
Potential biases in the review process
We performed a thorough literature search using formal search
strategies. At least two review authors independently identified tri-
als for inclusion and extracted data, thusminimising errors in these
aspects. We were unable to explore publication bias because of the
presence of only one trial in this review. However, we searched
the trial registers, which revealed only one trial on this topic. Pre-
gabalin is a relatively new discovery and we anticipate that trials
related to this topic are registered prospectively, so, the risk of re-
porting bias is small (Martindale 2011).
Agreements and disagreements with other
studies or reviews
This is the first review on this topic. We disagree with the trial
authors that pregabalin is an effective adjuvant therapy for treat-
ment of pain due to chronic pancreatitis because of the lack of
information on medium-term and long-term outcomes, and lack
of evidence on clinical benefits.
Chronic pancreatitis, as the name indicates, is a long-standing
disorder, with few deaths attributed to it (one to four per million
people (Dominguez-Munoz 2014; Spanier 2013)). However, it
might have a significant socioeconomic impact due to hospital
admissions and loss of work days due to chronic pain (Hall 2014).
A steady state of pregabalin levels can be reached in one to two days
(Martindale 2011), and one can expect the drug to have an effect
in one or two days (Gajraj 2007). Pregabalin has a relatively short
half-life, with amean eliminationhalf-life of 6.3hours (Martindale
2011). Based on this half-life, it is reasonable to expect the actions
of pregabalin to only last as long as it is being taken.
The only trial assessing the effect of pregabalin on patients with
chronic pain due to chronic pancreatitis administered pregabalin
to the participants for a period of three weeks. This period is not
sufficient to evaluate the beneficial and harmful effect of prega-
balin, since clinically, a patient might be required to take prega-
balin for a prolonged period of time for pain control. The clinical
significance of a change of short-term health-related quality of life,
opiate use, and pain scores from baseline was not evident, since the
trial was not powered to measure differences in clinical outcomes,
such as hospital admissions, and did not report on the work days
lost because of pain.
Participants taking pregabalin reported more adverse events than
those taking placebo, although the vast majority of these were
mild (Olesen 2011). Common adverse events related to pregabalin
include: dizziness, somnolence, blurred vision, diplopia (double
vision), dry mouth, constipation, vomiting, flatulence, eupho-
ria, confusion, reduced libido, erectile dysfunction, irritability,
vertigo, ataxia, tremor, dysarthria, paraesthesia, fatigue, oedema,
and disturbances of attention, memory, co-ordination, and gait
(Martindale 2011). These adverse events cannot be ignored.While
patients may develop tolerance to some adverse events, they may
not develop tolerance for others, such as somnolence (Kanbayashi
2014).
Thus, based on the lack of information onmedium-term and long-
term outcomes, and lack of evidence on clinical benefits, prega-
balin cannot be routinely recommended in patients with chronic
pain due to chronic pancreatitis. However, there is a need to con-
duct further randomised controlled trials on this topic because
of the socioeconomic impact of chronic pancreatitis. Such trials
should be powered to measure clinically relevant pain scores and
quality of life. For example, a trial comparing early surgery with
medical treatment followed by endoscopic treatment and surgi-
cal treatment (step-up approach) for chronic pancreatitis used a
minimum difference of 15 points on a visual analogue scale of 0
to 100, based on the results of a consensus meeting of an expert
panel (Ahmed Ali 2013). The trial authors estimated that a trial
would require approximately 88 participants to identify this min-
imal clinically important difference, based on an alpha of 0.05
and power of 0.90 (Ahmed Ali 2013). Given the nature of the
intervention, it is possible to conduct a trial at low risk of bias.
Such a trial should assess the medium or long-term effects of pre-
gabalin and should include outcomes such as: quality of life, treat-
ment-related adverse events, number of work days lost, number of
hospital admissions, and the length of hospital stay, to assess the
clinical and socioeconomic impact of using pregabalin in patients
with chronic pain due to chronic pancreatitis.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Based on low- to moderate-quality evidence, short-term prega-
balin decreases short-term opiate use, and short-term pain scores,
but increases adverse events compared to placebo, in people with
chronic pain due to chronic pancreatitis. The clinical implication
of reduced short-term opiate use and pain scores is not known.
Implications for research
Future trials assessing the role of pregabalin in decreasing pain in
chronic pancreatitis should assess themedium or long-term effects
of pregabalin, and should include outcomes such as: quality of
life, treatment-related adverse events, number of work days lost,
number of hospital admissions, and the length of hospital stay, in
addition to pain scores, to assess the clinical and socioeconomic
impact.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Olesen 2011
Methods Randomised controlled trial
Participants Country: The Netherlands and Denmark
Number randomised: 64
Post-randomisation drop-outs: 0 (0%)
Revised sample size: 64
Average age: 53 years
Females: 24 (37.5%)
Length of follow-up (weeks): 3
Number of study centres: 2
Inclusion criteria
1. Diagnosis of chronic pancreatitis based on the Mayo Clinic diagnostic criteria
2. Chronic abdominal pain typical for pancreatitis (i.e. dull epigastric pain more than 3
days per week for at least 3 months)
Exclusion criteria
1. Generalized painful conditions other than chronic pancreatitis
2. Pregnancy or lactation
3. Active (or history of ) major depression
4. Moderate to severe renal impairment
5. An abnormal electrocardiogram at screening
6. Hypersensitivity to pregabalin or any of its components
Interventions Participants were randomly assigned to two groups.
Group 1: pregabalin (N = 34).
Further details: Initial dose: 75mg pregabalin twice daily, increased to 150mg pregabalin
twice daily after 3 days, with a further increase to 300 mg twice daily after 1 week for
the rest of the study period (3 weeks).
Group 2: placebo (N = 30).
Further details: Matching placebo
Cointervention: Patients taking concomitant analgesic medication and expected to stay
on a stable regime during the trial were allowed to enter the study
Outcomes The outcomes reported were health quality of life, opiate analgesic requirement, adverse
events, pain scores, and hospital readmissions
Notes Source of funding: “Supported by a free grant from Pfizer Research and Development,
Hertha Christensen’s Foundation, and Christenson-Ceson’s Family Foundation”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization blocks had a size of six and were
computer-generated by a pseudo-random code”
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Olesen 2011 (Continued)
Allocation concealment (selection bias) Low risk Quote: “Pfizer donated pregabalin and identical capsules
containing placebo. Patients and those administrating
studymedication, assessing outcomes, and analyzing data
were blinded to group assignment”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Patients and those administrating study medica-
tion, assessing outcomes, and analyzing datawere blinded
to group assignment”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Patients and those administrating study medica-
tion, assessing outcomes, and analyzing datawere blinded
to group assignment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: There were no post-randomisation drop-
outs.
Selective reporting (reporting bias) Low risk Comment: All important outcomes were reported.
Other bias Low risk Comment: No other risks of bias were present.
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D A T A A N D A N A L Y S E S
Comparison 1. Pregabalin versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Health-related quality of life
(short-term)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2 Serious adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3 Opiate analgesic requirement in
mg (short-term)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4 Adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5 Pain scores (short-term) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
6 Hospital admissions 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
Analysis 1.1. Comparison 1 Pregabalin versus placebo, Outcome 1 Health-related quality of life (short-
term).
Review: Pregabalin for decreasing pancreatic pain in chronic pancreatitis
Comparison: 1 Pregabalin versus placebo
Outcome: 1 Health-related quality of life (short-term)
Study or subgroup Pregabalin Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Olesen 2011 34 9.7 (29.2) 30 -1.7 (30.5) 11.40 [ -3.28, 26.08 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours placebo Favours pregabalin
22Pregabalin for decreasing pancreatic pain in chronic pancreatitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.2. Comparison 1 Pregabalin versus placebo, Outcome 2 Serious adverse events.
Review: Pregabalin for decreasing pancreatic pain in chronic pancreatitis
Comparison: 1 Pregabalin versus placebo
Outcome: 2 Serious adverse events
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Olesen 2011 4/34 2/30 1.76 [ 0.35, 8.96 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 4 (Pregabalin), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pregabalin Favours placebo
Analysis 1.3. Comparison 1 Pregabalin versus placebo, Outcome 3 Opiate analgesic requirement in mg
(short-term).
Review: Pregabalin for decreasing pancreatic pain in chronic pancreatitis
Comparison: 1 Pregabalin versus placebo
Outcome: 3 Opiate analgesic requirement in mg (short-term)
Study or subgroup Pregabalin Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Olesen 2011 34 -30 (43.5) 30 -4 (43.5) -26.00 [ -47.36, -4.64 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours pregabalin Favours placebo
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Analysis 1.4. Comparison 1 Pregabalin versus placebo, Outcome 4 Adverse events.
Review: Pregabalin for decreasing pancreatic pain in chronic pancreatitis
Comparison: 1 Pregabalin versus placebo
Outcome: 4 Adverse events
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Olesen 2011 31/34 16/30 1.71 [ 1.20, 2.43 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 31 (Pregabalin), 16 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pregabalin Favours placebo
Analysis 1.5. Comparison 1 Pregabalin versus placebo, Outcome 5 Pain scores (short-term).
Review: Pregabalin for decreasing pancreatic pain in chronic pancreatitis
Comparison: 1 Pregabalin versus placebo
Outcome: 5 Pain scores (short-term)
Study or subgroup Pregabalin Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Olesen 2011 34 -36 (20) 30 -24 (20) -12.00 [ -21.82, -2.18 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours pregabalin Favours placebo
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Analysis 1.6. Comparison 1 Pregabalin versus placebo, Outcome 6 Hospital admissions.
Review: Pregabalin for decreasing pancreatic pain in chronic pancreatitis
Comparison: 1 Pregabalin versus placebo
Outcome: 6 Hospital admissions
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Olesen 2011 1/34 2/30 0.44 [ 0.04, 4.62 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 1 (Pregabalin), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pregabalin Favours placebo
A P P E N D I C E S
Appendix 1. Glossary of terms
Acute: sudden
Adenocarcinoma: cancer arising from glandular cells
Adjuvant: in addition to
Aetiology: cause
Analogue: a substance comparable to another substance (in this context)
Ataxia: loss of full control of body movements
Autoimmune: disease caused when the body’s defence mechanism, which usually protects against infections, reacts against and damages
the body’s own tissues.
Biliary obstruction: blockage to flow of bile
Biopsy: examination of a piece of tissue removed from a living body
Caerulein: a hormone that has a similar action to cholecystokinin (see below)
Calcifications: calcium deposits in tissue
CFTR mutation: alteration in the genetic code for a protein called cystic fibrosis transport regulator (CFTR)
Chemotherapy: the use of medication to treat or control a disease
Cholecystokinin: a hormone that increases the contractility of the gallbladder, thus increasing the flow of bile into the small bowel
Chronic: long-standing
Coeliac plexus block: an injection of long-acting local anaesthetic into the coeliac plexus, a network of nerves that supply the abdominal
organs
Computed tomography (CT scan): This is performed by taking a series of X-rays using special equipment, and processing the images
using a computer to obtain a final image.
Concomitant: at the same time (in this context)
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Diabetes: a lifelong condition that causes a person’s blood sugar level to become too high
Digestive enzyme deficiency: shortage of enzymes that help with digestion by breaking down the food that we eat into substances
that can be absorbed from the gut
Duodenal aspirate: fluid obtained from the upper part of the small intestine, usually with a tube inserted into the small intestine
through the nose or mouth
Duodenum: upper part of small bowel. It conducts digested food from the stomach to the middle part of the small bowel (jejunum).
The bile duct and the pancreatic duct conduct the bile and pancreatic juice to drain into the duodenum.
Dysarthria: slurred speech
Dyspnoea: shortness of breath
Elastase: enzyme that breaks down protein
Endocrine pancreatic insufficiency: deficiency of hormones secreted from cells in the pancreas, clinically manifesting as diabetes
because of insulin deficiency
Endoscopic retrograde cholangio pancreatography: a diagnostic test that involves the use of an endoscope and x-rays to image the
pancreas and biliary system
Endoscopic ultrasound: an ultrasound scan that is performed using an endoscope.
Enzyme: substances (usually proteins) originating from living cells and capable of producing specific chemical changes in organic
substances by catalytic action
Euphoria: feeling of high excitement
Exocrine pancreas: part of the pancreas that secretes pancreatic juice
Exocrine pancreatic insufficiency: deficiency of pancreatic digestive enzymes
Fibromyalgia: muscle or joint pain with stiffness and localised pain at specific points on the body
Gait: the way one walks
Gynaecomastia: enlargement of male breasts
High-voltage-gated calcium channels: these are activated when a nerve impulse arrives and allows movement of calcium into the
cells, which in turn, activates other molecular activities, including muscle contraction and excitation of neurons.
Histopathological: examination of tissue under the microscope
Hypercalcaemia: high calcium in blood
Hyperparathyroidism: high parathormone levels (a hormone involved in maintaining calcium level) in blood
Hypertension: high blood pressure
Idiopathic: cause of disease could not be identified
Insulin: substance that helps regulate blood sugar
Libido: sexual desire
Metastatic: spread of cancer to other parts of the body
Mortality: death
Neural: nerve-related
Neurolysis: destruction of a nerve (in this context, using injection of chemicals such as 100% alcohol (absolute alcohol) or by heat
generated by radiofrequency waves)
Neuropathic pain: pain due to a disease affecting the somatosensory system (part of the nerve system concerned with sensations, such
as touch, pressure, pain, and temperature)
Neurotransmitter: a chemical substance released from the end of a nerve fibre when a nerve impulse arrives. Neurotransmitters are
responsible for transmission of sensations and for muscle contraction.
Oedema: swelling
Pancreatic pseudocysts: fluid collections in the pancreas or the tissues surrounding the pancreas, surrounded by a well-defined wall,
and containing only fluid, with little or no solid material
Parenchyma: the essential element of the organ, as opposed to the supporting tissue
Paraesthesia: tingling sensation
Pathogenesis: development of a disease
Peripancreatic: around the pancreas
Placebo: sham or dummy treatment
Prognosis: outlook (in this context, outlook for survival)
Radiotherapy: use of radiation to treat a disease
Renal: kidney
Rhabdomyolysis: destruction of voluntary muscles
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Secretin enhanced magnetic resonance cholangiopancreatography: a magnetic resonance scan (MRI) performed after administering
secretin (a hormone that regulates the secretion of the stomach and pancreas)
Sensory fibres: nerve fibres that carry sensations, including pain
Somnolence: sleepiness
SPINK 1 mutation: alteration in the genetic code for a protein called serine protease inhibitor Kazal-type 1 (SPINK 1)
Steatorrhoea: bulky, foul smelling stools, due to the presence of excessive fat in the stools
Surgical resection: surgical removal
Sympathetic fibres: nerve fibres that control involuntary actions in the body, such as control of blood pressure
Systemic: all over the body (in this context)
Thiazide: a medicine used to lower blood pressure by increasing the excretion of salt and water from body
Urticaria: rash of round, red wheals on the skin that itch intensely
Valproate: a medicine used in people with epilepsy
Vertigo: a sensation of spinning of the head or the environment and loss of balance
Appendix 2. CENTRAL search strategy
#1 pancreas
#2 pancrea*
#3 MeSH descriptor: [Pancreas] explode all trees
#4 chronic pancreatitis
#5 MeSH descriptor: [Pancreatitis, Chronic] explode all trees
#6 #1 or #2 or #3 or #4 or #5
#7 pregabalin or Lyrica
#8 #6 and #7
Appendix 3. MEDLINE search strategy
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. exp animals/ not humans.sh.
11. 9 not 10
12. exp Pancreatitis, Chronic/
13. chronic pancreatitis.mp.
14. 12 or 13
15. exp Pancreaticoduodenectomy/
16. exp Pancreatectomy/
17. (pancreaticoduodenectomy or pancreaticoduodenectomies or duodenopancreatectomy or duodenopancreatectomies or pancreate-
ctomy).mp.
18. 15 or 16 or 17
19. 11 and 14 and 18
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Appendix 4. EMBASE search strategy
1. (pancreas or pancrea*).mp.
2. exp pancreas/
3. chronic pancreatitis.mp.
4. exp Pancreatitis, Chronic/
5. 1 or 2 or 3 or 4
6. (pregabalin* or Lyrica).mp.
7. exp pregabalin/
8. 6 or 7
9. 5 and 8
10. Clinical trial/
11. Randomized controlled trial/
12. Randomization/
13. Single-Blind Method/
14. Double-Blind Method/
15. Cross-Over Studies/
16. Random Allocation/
17. Placebo/
18. Randomi?ed controlled trial*.tw.
19. Rct.tw.
20. Random allocation.tw.
21. Randomly allocated.tw.
22. Allocated randomly.tw.
23. (allocated adj2 random).tw.
24. Single blind*.tw.
25. Double blind*.tw.
26. ((treble or triple) adj blind*).tw.
27. Placebo*.tw.
28. Prospective study/
29. or/10-28
30. Case study/
31. Case report.tw.
32. Abstract report/ or letter/
33. or/30-32
34. 29 not 33
35. 9 and 34
Appendix 5. Science Citation Index search strategy
# 1 TS=(chronic pancreatitis or pancreas or pancrea*)
# 2 TS=(pregabalin* or Lyrica)
# 3 TS=(random* OR rct* OR crossover OR masked OR blind* OR placebo* OR meta-analysis OR systematic review* OR meta-
analys*)
# 4 #3 AND #2 AND #1
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Appendix 6. ClinicalTrials.gov search strategy
“Interventional” [STUDY-TYPES] AND (“Phase 2” OR “Phase 3” OR “Phase 4”) [PHASE] | chronic pancreatitis | pregabalin
Appendix 7. WHO ICTRP search strategy
pancrea* AND pregabalin
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We revised the time period of short-term outcome from ’four weeks to three months’ to ’two weeks to three months’ to include the
immediate benefits of pregabalin.
We assessed the hospital admissions as a binary outcome, since the only trial included in this review reported the number of participants
requiring readmission rather than the number of hospital admissions.
30Pregabalin for decreasing pancreatic pain in chronic pancreatitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
